Find medication to prevent new COVID-19 infections and protect the population at risk from already marketed medication
Hundreds of thousands of people have been diagnosed with COVID-19. The SARS-CoV-2 virus, named after the pneumonia outbreak that erupted in December 2019 in Wuhan, China, is responsible for the disease. To date, this virus in the Coronaviridae family has spread to many countries, affecting Asia, Africa, Europe and the Americas, and has been declared a pandemic by the World Health Organization.
In addition to mitigating the morbidity and mortality associated with COVID-19, in outbreaks like this, preventing the appearance of so-called "secondary cases" is an essential strategy. These secondary cases refer to people who are infected by direct contact with patients with the disease - health personnel and family members, mainly. In addition to perpetuating the spread of the disease, infection by healthcare professionals poses a serious problem in healthcare settings.
The objective of this project is to break the coronavirus transmission chain by using existing medication. The team led by researchers from the Institute for Global Health (ISGlobal) and the Hospital Clínic will explore the efficacy of medicines already on the market to prevent new infections and protect the population at risk, especially health workers and people who are in contact with cases affected by SARS-CoV-2.
- Test the efficacy of other antiviral drugs onin the market is currently being tested.
- Conduct clinical assays to test the efficacy of new treatments.
Patients affected by COVID-19 across the world.
ISGlobal (web)